ClinicalTrials.gg
WithdrawnNCT04675450Updated Jun 8, 2023

NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy

A Phase 2 interventional study of Placebo and NBP Softgel Capsules in Breast Cancer and Peripheral Neuropathy, sponsored by Conjupro Biotherapeutics, Inc.. Withdrawn. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-08.

Sponsored by Conjupro Biotherapeutics, Inc. · Phase 2, Interventional, and Prevention

How we know

Why this study was withdrawn
Further preclinical development activities required to proceed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Phase 2, randomized, double-blind, Placebo-Controlled, Multiple Dose Study for the treatment of Patients with Metastatic Breast Cancer.

Read the detailed description

This is a multiple center, randomized, double-blind, Phase 2 study of NBP administered to women with metastatic breast cancer who receive nab-paclitaxel as therapy. Nab-paclitaxel will be administered at a dose >260 mg/m2 every 3 weeks for 4 planned cycles. Subjects will begin receiving NBP orally at a dose of 400 mg administered every 12-hours (BID) or matching placebo 5 days (10 doses) prior to starting nab-paclitaxel therapy and continue to self-administer it BID until Visit 6/Day 100/Week 15. The primary objective is to evaluate the efficacy of NBP relative to placebo at preventing or reducing symptoms associated with nab-paclitaxel induced toxic neuropathy (CIPN). The secondary objectives include an evaluation the efficacy of NBP relative to placebo at preventing or attenuating taxane induced acute pain syndrome (TAPS), the evaluation of the safety and tolerability of NBP relative to placebo and to determine if NBP administration impacts the pharmacokinetics of nab-paclitaxel or if nab-paclitaxel affects the pharmacokinetics of NBP.

02

Conditions studied

  • Breast Cancer
  • Peripheral Neuropathy
03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Lead sponsor

Conjupro Biotherapeutics, Inc. is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria

Subjects are eligible to participate in the study only if all the following criteria apply:

  1. Women aged ≥18 and ≤75 years.
  2. confirmed breast cancer.
  3. Are candidates for initial therapy with nab-paclitaxel, at a dose of >260 mg/m2 every 3 weeks for 4 planned cycles.
  4. Concomitant antitumor drugs used to treat the underlying , including immunotherapies, other than nab-paclitaxel will be allowed.
  5. (ECOG) performance status scores of 0 - 2.
  6. ≥6 months.
  7. Women of (WOCBP) must have a negative serum human chorionic gonadotropin (HCG) pregnancy test at Screening and be practicing a medically acceptable method of with an annual failure rate of less than 1% until the completion of the trial or 30 days after discontinuation of study treatment. Women are considered not childbearing if they are >1 year or surgically sterile (ie, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy tubal ligation).
  8. Able to complete study questionnaires by themselves or with assistance.
  9. Capable of understanding the purpose and risks of the study and able to provide by signing the informed consent form.
  10. Able to swallow softgel capsules as determined by the investigator.
  11. Able to comply with all study requirements. Exclusion Criteria

Subjects are excluded from the study if any of the following criteria apply:

  1. Non-metastatic breast cancer.
  2. Subjects who are pregnant, lactating/breast-feeding, or plan to become pregnant within the next 3 months.
  3. History of poorly controlled diabetes mellitus ( >8.0 at the time of the Screening visit).
  4. History of fibromyalgia.
  5. History of any signs or symptoms suggestive of neuropathy within 30 days of Screening as determined by the investigator based on the neurological examination.
  6. History of taking any neurotoxic drugs within 6 months of Screening.
  7. Current use of drugs that are used to treat neuropathic pain (eg, gabapentin, pregabalin, and duloxetine) within 30 days of Screening.
  8. Current diagnosis of malignancy other than breast cancer.
  9. \<1.5 x 109 cells/L.
  10. count \<100,000 x 109/L.
  11. level \<9 g/dL at Screening without transfusion (transfusion independent).
  12. Corrected >470 msec (single tracing) at Screening and prior to randomization.
  13. Chronic renal or hepatic disease.
  14. renal dysfunction including serum creatinine level >1.5 mg/dL or calculated ≥50 mL/minute at Screening.
  15. (ALT) or aspartate aminotransferase (AST) level >2.0 x (ULN), or a >1.5 x ULN unless in the setting of known Gilbert's disease at Screening.
  16. History of , , , or tuberculosis.
  17. Major surgical procedures ≤30 days prior to starting study drug, or minor surgical procedures ≤7 days prior to starting study drug.
  18. History of alcohol or drug dependence or is known to have abused alcohol within 30 days prior to screening.
  19. Unwilling to abstain from alcohol and recreational drugs (with exception for medical marijuana) throughout the duration of participation in the study.
  20. Positive urine drug screen at Screening (with exception for medical marijuana which is allowed).
  21. Known to celery or soybeans.
  22. Known serious hypersensitivity to paclitaxel
  23. Received treatment with any other drug within 30 days before screening, was previously treated with NBP, is currently taking celery seed extract, or is currently participating in another clinical study
  24. Any other reasons that in the opinion of the investigator make the subject unsuitable for enrollment.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Interventions: Placebo (NBP placebo softgel capsules, 0 mg NBP, BID)

    Drug: Placebo

  • Active comparator
    NBP

    Interventions: 800 mg NBP softgel capsules daily (400 mg BID)

    Drug: NBP Softgel Capsules

Interventions

  • DrugPlacebo

    Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing

    Also known as: NBP Placebo Softgel Capsules

  • DrugButylphthalideStudies of ButylphthalideButylphthalide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.

    Also known as: NBP

06

What researchers measure

Primary outcomes

  1. Mean Change from Baseline in EORTC Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy (EORTC QLQ-CIPN20) Sensory Subscale

    Change from baseline in the mean EORTC QLQ-CIPN20 sensory subscale (converted to a 0-100 scale) collected during the treatment period at weeks 5, 8, 11 and 15.

    Time frame: Baseline and weeks 5, 8, 11 and 15

Secondary outcomes

  1. Number of Participants Requiring Rescue Medication

    The number and percentage of participants requiring oxycodone of any amount anytime during the 15 week treatment period.

    Time frame: 15 weeks

  2. Days Free of Rescue Medication

    The mean cumulative number of days free of oxycodone of any amount anytime for each participant during the 15 week treatment period.

    Time frame: 15 weeks

  3. Mean Change from Baseline in the Brief Pain Inventory Short Form (mBPI-SF) score.

    The mean change from baseline (mean days 2-7 after first dose of NBP or Placebo) in the mBPI-SF total score to mean of all post-nab-paclitaxel mBPI-SF scores collected on days 2-7 after each of 4 nab-paclitaxel administration at days 7, 28, 49 and 70 during the 15 week treatment period.

    Time frame: 15 weeks

  4. Number of Participants with Treatment-Emergent Adverse Events

    The number and percentage of participants with treatment-emergent adverse events according to MedDRA system organ class and preferred term with onset during the 15 week treatment period or 4 week follow-up.

    Time frame: 19 weeks

  5. Area Under the Curve (AUC) for NBP

    The AUC (h\*ng/mL) be calculated using Phoenix WinNonlin software

    Time frame: 0, 1.5, 3, 4, 6, 8 and 24 hours - Days 6 and 7

  6. Cmax for NBP

    Cmax (ng/mL) be calculated using Phoenix WinNonlin software

    Time frame: Time Frame: 0, 1.5, 3, 4, 6, 8 and 24 hours - Days 6 and 7

  7. Tmax for NBP

    Tmax (hr) be calculated using Phoenix WinNonlin software

    Time frame: 0, 1.5, 3, 4, 6, 8 and 24 hours - Days 6 and 7

  8. Area Under the Curve for Paclitaxel

    AUC (h\*ng/mL) be calculated using Phoenix WinNonlin software

    Time frame: 0, 1.5, 3, 4, 6, 8 and 24 hours - Days 6 and 7

  9. Cmax for Paclitaxel

    Cmax (ng/mL) be calculated using Phoenix WinNonlin software

    Time frame: 0, 1.5, 3, 4, 6, 8 and 24 hours - Days 6 and 7

  10. Tmax for Paclitaxel

    Tmax (hr) be calculated using Phoenix WinNonlin software

    Time frame: Time Frame: 0, 1.5, 3, 4, 6, 8 and 24 hours - Days 6 and 7

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2023; primary completion for Dec 2024, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2020
First posted
Dec 19, 2020
StartEst.
Jun 30, 2023
Primary completionEst.
Dec 30, 2024
CompletionEst.
Jan 30, 2025
Last update
Jun 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04675450
Lead sponsor
Conjupro Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 19, 2020
Start date
Jun 30, 2023 (estimated)
Primary completion
Dec 30, 2024 (estimated)
Completion
Jan 30, 2025 (estimated)
Last update
Jun 8, 2023

Study contacts

Qingxi Wang, PhD
study director · Conjupro Biotherapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Butylphthalide

Start the discussion